MX2018013517A - Anticuerpos anti-il-1r3 humanizados. - Google Patents
Anticuerpos anti-il-1r3 humanizados.Info
- Publication number
- MX2018013517A MX2018013517A MX2018013517A MX2018013517A MX2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A MX 2018013517 A MX2018013517 A MX 2018013517A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody
- cancer
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención actual se refiere a anticuerpos humanizados que se enlazan específicamente a IL-1R3 o un fragmento o derivado del mismo o un polipéptido que contiene al menos una porción de dicho anticuerpo que es suficiente para conferir especificidad de enlace IL-1R3. Dichos anticuerpos inhiben la actividad NFkB inducida por IL-1R3. También inhiben la actividad NFkB estimulada por IL-1alfa, IL-1beta, IL-33, e/o IL-36. La descripción se refiere además al uso de dicho anticuerpo humanizado en el tratamiento de una enfermedad mediada por IL-1R3 tal como cáncer. La descripción abarca finalmente una composición farmacéutica que comprende un portador farmacéuticamente aceptable y una cantidad terapéuticamente efectiva del anticuerpo de acuerdo con la invención. La composición farmacéutica puede usarse en el tratamiento de una enfermedad mediada por IL-1R3 tal como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168617.5A EP3241845A1 (en) | 2016-05-06 | 2016-05-06 | Humanized anti-il-1r3 antibodies |
| PCT/EP2017/060925 WO2017191325A1 (en) | 2016-05-06 | 2017-05-08 | Humanized anti-il-1r3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013517A true MX2018013517A (es) | 2019-07-08 |
Family
ID=55919721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013517A MX2018013517A (es) | 2016-05-06 | 2017-05-08 | Anticuerpos anti-il-1r3 humanizados. |
| MX2023002554A MX2023002554A (es) | 2016-05-06 | 2018-11-05 | Anticuerpos anti-il-1r3 humanizados. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002554A MX2023002554A (es) | 2016-05-06 | 2018-11-05 | Anticuerpos anti-il-1r3 humanizados. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11203642B2 (es) |
| EP (3) | EP3241845A1 (es) |
| JP (3) | JP7038462B2 (es) |
| KR (3) | KR20230107695A (es) |
| CN (3) | CN116178549A (es) |
| AU (2) | AU2017260399B2 (es) |
| BR (1) | BR112018072681A8 (es) |
| CA (1) | CA3022657A1 (es) |
| DK (1) | DK3452513T3 (es) |
| EA (1) | EA201892541A1 (es) |
| ES (1) | ES2982075T3 (es) |
| FI (1) | FI3452513T3 (es) |
| HR (1) | HRP20240961T1 (es) |
| HU (1) | HUE066965T2 (es) |
| IL (2) | IL262776B2 (es) |
| LT (1) | LT3452513T (es) |
| MX (2) | MX2018013517A (es) |
| NZ (1) | NZ748130A (es) |
| PL (1) | PL3452513T3 (es) |
| PT (1) | PT3452513T (es) |
| RS (1) | RS65804B1 (es) |
| SG (1) | SG11201809764XA (es) |
| SI (1) | SI3452513T1 (es) |
| WO (1) | WO2017191325A1 (es) |
| ZA (1) | ZA201807167B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| WO2018162724A1 (en) | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| CA3192323A1 (en) | 2020-09-14 | 2022-03-17 | Julie MACOIN | Antibodies that bind to il1rap and uses thereof |
| CN117062836A (zh) * | 2021-02-05 | 2023-11-14 | 勃林格殷格翰国际有限公司 | 抗il1rap抗体 |
| US20220411517A1 (en) | 2021-05-21 | 2022-12-29 | Leo Pharma A/S | IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof |
| US11958899B2 (en) * | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| AU2023345467A1 (en) | 2022-09-21 | 2025-05-08 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| CN116574189A (zh) * | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| CN116284401B (zh) * | 2023-02-20 | 2024-09-24 | 中国人民解放军军事科学院军事医学研究院 | 人源抗il-1r3抗体及其应用 |
| CN120131991A (zh) * | 2023-12-13 | 2025-06-13 | 成都百利多特生物药业有限责任公司 | 抗人Claudin18.2抗体-喜树碱类药物偶联物及其医药用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
| DE69126281T2 (de) | 1990-11-26 | 1997-10-16 | Akzo Nobel Nv | Verfahren zur Herstellung von Antikörpern |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US6280955B1 (en) | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| AU2002253842A1 (en) | 2000-10-31 | 2002-08-28 | Immunex Corporation | Il-1 receptor accessory protein |
| AU2002324625B2 (en) | 2001-08-07 | 2008-05-08 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
| EP2277543B1 (en) | 2002-09-06 | 2015-12-16 | Amgen, Inc | Therapeutic anti-IL-1R1 monoclonal antibody |
| ATE475708T1 (de) | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
| US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| WO2005035727A2 (en) | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
| ES2708095T3 (es) | 2003-11-05 | 2019-04-08 | Roche Glycart Ag | Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas |
| JP2007522118A (ja) | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
| JP2007519422A (ja) | 2004-02-02 | 2007-07-19 | アンブレツクス・インコーポレイテツド | 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用 |
| EP2343363A1 (en) | 2005-07-01 | 2011-07-13 | John Schrader | Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining |
| KR101379568B1 (ko) | 2005-08-26 | 2014-04-08 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
| NZ572807A (en) | 2006-05-19 | 2011-10-28 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells |
| WO2009120899A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | G coupled protein receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2408817B1 (en) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Bispecific anti-her antibodies |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CN102939304B (zh) | 2010-04-09 | 2017-04-19 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| PL2400298T3 (pl) | 2010-05-28 | 2014-01-31 | Hoffmann La Roche | Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał |
| JP5940093B2 (ja) | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
| FI2691417T4 (fi) | 2011-03-29 | 2025-01-14 | Roche Glycart Ag | Vasta-aineen Fc-variantteja |
| US20140308294A1 (en) * | 2011-04-15 | 2014-10-16 | Merck Patent Gmbh | Anti-IL-1R1 Inhibitors For Use in Cancer |
| CA2837651A1 (en) * | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| WO2014113433A1 (en) | 2013-01-16 | 2014-07-24 | George Mason University | Binding domain mapping |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US20150315179A1 (en) | 2014-05-02 | 2015-11-05 | Torrey Pines Institute For Molecular Studies | Compounds and methods of treating neurological disorders |
| GB201413913D0 (en) * | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
-
2016
- 2016-05-06 EP EP16168617.5A patent/EP3241845A1/en not_active Withdrawn
-
2017
- 2017-05-08 KR KR1020237021882A patent/KR20230107695A/ko not_active Ceased
- 2017-05-08 CN CN202211533431.5A patent/CN116178549A/zh active Pending
- 2017-05-08 KR KR1020227010275A patent/KR102550643B1/ko active Active
- 2017-05-08 US US16/099,059 patent/US11203642B2/en active Active
- 2017-05-08 WO PCT/EP2017/060925 patent/WO2017191325A1/en not_active Ceased
- 2017-05-08 DK DK17724778.0T patent/DK3452513T3/da active
- 2017-05-08 AU AU2017260399A patent/AU2017260399B2/en active Active
- 2017-05-08 PT PT177247780T patent/PT3452513T/pt unknown
- 2017-05-08 EP EP17724778.0A patent/EP3452513B1/en active Active
- 2017-05-08 EA EA201892541A patent/EA201892541A1/ru unknown
- 2017-05-08 IL IL262776A patent/IL262776B2/en unknown
- 2017-05-08 CN CN202211533197.6A patent/CN116178548A/zh active Pending
- 2017-05-08 EP EP24169816.6A patent/EP4434540A3/en active Pending
- 2017-05-08 PL PL17724778.0T patent/PL3452513T3/pl unknown
- 2017-05-08 KR KR1020187034930A patent/KR102381257B1/ko active Active
- 2017-05-08 BR BR112018072681A patent/BR112018072681A8/pt active Search and Examination
- 2017-05-08 LT LTEPPCT/EP2017/060925T patent/LT3452513T/lt unknown
- 2017-05-08 CN CN201780041725.7A patent/CN109415442B/zh active Active
- 2017-05-08 ES ES17724778T patent/ES2982075T3/es active Active
- 2017-05-08 MX MX2018013517A patent/MX2018013517A/es unknown
- 2017-05-08 HR HRP20240961TT patent/HRP20240961T1/hr unknown
- 2017-05-08 JP JP2019510473A patent/JP7038462B2/ja active Active
- 2017-05-08 HU HUE17724778A patent/HUE066965T2/hu unknown
- 2017-05-08 SI SI201731536T patent/SI3452513T1/sl unknown
- 2017-05-08 RS RS20240776A patent/RS65804B1/sr unknown
- 2017-05-08 IL IL297527A patent/IL297527A/en unknown
- 2017-05-08 FI FIEP17724778.0T patent/FI3452513T3/fi active
- 2017-05-08 NZ NZ748130A patent/NZ748130A/en unknown
- 2017-05-08 SG SG11201809764XA patent/SG11201809764XA/en unknown
- 2017-05-08 CA CA3022657A patent/CA3022657A1/en active Pending
-
2018
- 2018-10-26 ZA ZA2018/07167A patent/ZA201807167B/en unknown
- 2018-11-05 MX MX2023002554A patent/MX2023002554A/es unknown
-
2021
- 2021-08-24 US US17/410,153 patent/US12024564B2/en active Active
-
2022
- 2022-03-03 JP JP2022032317A patent/JP7480199B2/ja active Active
-
2024
- 2024-04-23 JP JP2024069425A patent/JP2024102134A/ja active Pending
- 2024-05-20 US US18/668,446 patent/US20240409644A1/en active Pending
- 2024-06-13 AU AU2024204004A patent/AU2024204004A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013517A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EP4623992A3 (en) | Antibodies specifically binding to human il-1r7 | |
| PH12017500949A1 (en) | Human antibodies to influenza hemagglutinin | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| MY196224A (en) | Human Antibodies To Ebola Virus Glycoprotein | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| NI201500002A (es) | Agentes de unión de rspo3 y usos de los mismos. | |
| CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
| ECSP18010616A (es) | Inmunoconjugados de il22 | |
| AR104361A1 (es) | Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |